HOME > COLUMN
COLUMN
-
Recruitment: Save Yourself from the Insanity of Diminished Returns
November 22, 2013
-
Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 2
November 8, 2013
-
Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 1
November 7, 2013
-
A World of Opportunity for the Brave
November 1, 2013
-
Does HR Have an Image Problem?
September 20, 2013
-
Learn How to Give a Great Presentation and You May Break the “Gaijin Ceiling” to the Board Room at Headquarters
August 21, 2013
-
Watch out for the Gorilla when Hiring Talent
July 19, 2013
-
Great Leaders Are Happy to Eat Humble Pie and Give the Credit to Others
June 21, 2013
-
Lessons Learned from the Firing Line of Interviewing in a Bi-lingual and Bi-cultural Environment
May 23, 2013
-
An Insider’s Perspective on Hiring in Japan
April 26, 2013
-
Pharmaceutical Companies in Japan Cross Cultural Boundaries to Retain and Hire the Best and the Brightest
March 18, 2013
-
Ichi-go Ichi-e - “One Opportunity, One Encounter”
February 20, 2013
-
Our Habits Are the Nuts and Bolts of Our Destiny
January 22, 2013
-
What Are Japanese Pharmaceutical Candidates Thinking?
December 18, 2012
-
Mid-Level Managers Seek More Guidance and Global Opportunities from Their Senior Management at Japan’s Multinational Pharmaceutical Companies
November 19, 2012
-
Leading from Afar
October 22, 2012
-
“Make Up Your Own Mind? What It Takes to Win Over Top-Tier Japanese Employees”
September 18, 2012
-
Our Habits Determine Our Success
August 8, 2012
-
Marketing Is More than a Pen and a Tissue Box
July 9, 2012
-
Science without Works Is Dead
June 4, 2012
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…